Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 in Relapsed or Refractory Autoimmune Cytopenia
NCT07175493Phase 2Recruiting
- Sponsor
- Keymed Biosciences
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gamgertamig in immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), Evans syndrome and 1 more, sponsored by Keymed Biosciences. Primary endpoints: Incidence and Severity of Adverse Events and Serious Adverse Events at 52 weeks, Efficacy of CM336 at 8 weeks and 2 more. Started Nov 2025; status: recruiting.
02
Drugs
gamgertamig
03
Conditions
immune thrombocytopenia (ITP)autoimmune hemolytic anemia (AIHA)Evans syndromeautoimmune cytopenia
Beyond the preview
Go deeper on NCT07175493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07175493.